Details of the Company’s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2026 are as follows:
| Name of Subsidiary |
|
Place and Date of Incorporation |
|
Percentage of Ownership |
|
Principal Activities |
| Avalon Healthcare System, Inc. (“AHS”) |
|
Delaware
May 18, 2015 |
|
100% held by
ALBT |
|
Holding company for payroll and other expenses |
| |
|
|
|
|
|
|
| Avalon (Shanghai) Healthcare Technology Co., Ltd. (“Avalon Shanghai”) |
|
PRC
April 29, 2016 |
|
100% held by
AHS |
|
Not considered an operating entity |
| Genexosome Technologies Inc. (“Genexosome”) |
|
Nevada
July 31, 2017 |
|
60% held by
ALBT |
|
No current
activities to report; dormant |
| |
|
|
|
|
|
|
| Avalon Laboratory Services, Inc. (“Avalon Lab”) |
|
Delaware
October 14, 2022 |
|
100% held by
ALBT |
|
No current activities to report; dormant |
| Q&A Distribution LLC (“Q&A Distribution”) |
|
Texas
May 1, 2024 |
|
100% held by
ALBT |
|
Distributes KetoAir device |
| Nexus MergerSub Limited (“Nexus”) |
|
BVI
February 21, 2025 |
|
100% held by
ALBT |
|
No current activities to report |
| |
|
|
|
|
|
|
| Avalon Quantum AI, LLC (“Avalon Quantum AI”) |
|
Nevada
December 5, 2025 |
|
100% held by
ALBT |
|
Is advancing next-generation agentic AI systems targeted to consumers and small businesses, starting with an SaaS automated video production
platform |
|